Background

Resveratrol is a stilbene-based phytochemical, which possesses multiple pharmacological activities. However, the low bioavalibility of resveratrol mystifies its pharmacology.

Scope and approach

We discussed the reciprocal interactions of resveratrol with gut microbiota as investigated by in vitro, animal models as well as humans studies.

Key findings and conclusions

The first part described the current in vitro and in vivo evidence concerning the modulative effect of resveratrol on gut microbiota composition, particularly focusing on the involvement of gut microbiota modulation in the anti-diabetic, anti-obesity, and anti-atherosclerosis effects of resveratrol. The second part summarized the bioconversion of resveratrol by gut microbiota, and the identification of metabolites along with bacterial species as generators of these metabolites. This may not only help reconcile the bioavailability conundrum of resveratrol, but also provide directions to expedite its medical applications.

中文翻译：

---

白藜芦醇和肠道菌群之间的相互相互作用加深了我们对其潜在健康益处的分子机制的了解

背景

白藜芦醇是一种基于sti的植物化学物质，具有多种药理活性。然而，白藜芦醇的低生物利用度使它的药理学神秘化。

范围和方法

我们讨论了白藜芦醇与肠道菌群的相互作用，如体外，动物模型以及人体研究。

主要发现和结论

第一部分描述了有关白藜芦醇对肠道菌群组成的调节作用的当前体外和体内证据，特别是关注肠道菌群调节与白藜芦醇的抗糖尿病，抗肥胖和抗动脉粥样硬化作用有关。第二部分概述了肠道菌群对白藜芦醇的生物转化，并鉴定了代谢产物以及细菌作为这些代谢产物的产生者。这不仅可以帮助调和白藜芦醇的生物利用度难题，还可以提供加快其医学应用的方向。